Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 1999

View Archived Issues

Company Profile: ExonHit Therapeutics

Company Profile: Cytokinetics

Licensing opportunity from Cornell Research Foundation: methods of modulating immune responses

Immunex and Genentech reach TRAIL/Apo2L oncology agreement

AVI BioPharma to initiate phase II clinical trial of Avicine in pancreatic cancer

Alteon completes phase I human trials of ALT-711

Cell Pathways updates clinical status of SAANDs

Watson reacquires North American marketing rights to Androderm

Pharming updates product pipeline

New compounds from SS Pharm. with greater bladder selectivity than oxybutynin

Pfizer claims PDE1 inhibitors for range of cardiovascular and other disorders

Kyowa Hakko presents new phosphodiesterase inhibitors

Interferon inducers in development at Hokuriku Seiyaku

Fujisawa studies inhibitors of vacuolar H+-ATPase as bone resorption inhibitors

Idec presents interim phase I/II results with clenoliximab at EULAR congress

Ligands of brain nACh receptors designed at NeuroSearch

Roche's new vitamin D derivative proves superior to calcitriol in early pharmacological testing

Lornoxicam available in Germany for arthritic conditions

SBIR award to CoCensys to discover caspase inhibitors for stroke

FDA says 3M's inhaled corticosteroid in CFC-free inhaler approvable for asthma

In vitro studies shed light on the mechanism of action of triptolide

GenVec obtains rights to patents covering HSV vectors for gene therapy in nervous system disorders

Wyeth Lederle Vaccines submits PLA for pneumococcal vaccine

Immune Response's membrane-bound cytokine-containing antitumor vaccines covered by U.S. patent

Fludarabine and other specific STAT1-targeting drugs as potential immunosuppressants

Fujisawa works to expand the clinical indications of tacrolimus

Patient treatment completed in pivotal ranolazine trial in angina

Approval recommended for nateglinide in Japan

Effects of T-588 on cerebral function studied in rats

Angiogenesis inhibitor SU-5416 poised to enter phase III testing in U.S. and Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...